<DOC>
	<DOC>NCT01159626</DOC>
	<brief_summary>This Phase 1 study is the first clinical trial in Japanese subjects. The study is designed to evaluate the single- and multiple-dose pharmacokinetics, safety and tolerability of PF-03463275 oral controlled release formulation in Japanese and Western male subjects.</brief_summary>
	<brief_title>Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male subjects between the ages of 18 and 55 years. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2, and a total body weight &gt;50 kg (110 lbs). Japanese subjects must have four Japanese grandparents who were born in Japan. Subjects that are genotyped to be PM (poor metabolizer), UM (ultrarapid metabolizer), IM/EM and EM/UM for CYP2D6 status. Evidence or history of clinically significant hematological (including anemia), renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Phase1</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy Male</keyword>
	<keyword>Japanese</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>